Skip to main content
Clinical Trials/KCT0002512
KCT0002512
Recruiting
未知

Phase II, randomized, double-blind clinical trial for efficacy of Granulocyte-colony stimulating factor(G-CSF) and autologous cord blood infusion in children with cerebral palsy

Hanyang University Seoul Hospital0 sites98 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Hanyang University Seoul Hospital
Enrollment
98
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Hanyang University Seoul Hospital

Eligibility Criteria

Inclusion Criteria

  • ¦A patient who was diagnosed with a mild case, and severity case of cerebral palsy or developmental disability through developmental assessment from more than two specialists including a specialist in pediatrics and rehabilitation medicine
  • ¦Aged 2\~10(in full)
  • ¦In case there is a sign of the general decrease in white matter, or periventricular leukomalacia near cerebral ventricles in MRI\-DTI(photographed before a clinical trial)test
  • ¦A subject who did a written consent to participation in this clinical trial through the very person and a legal representative\-a guardian

Exclusion Criteria

  • ¦ In case a patient underwent a surgical procedure, or was administered medicated medicine which are known to have neuroprotective effects even partially, such as autologous cord blood and erythropoietin, and Granulocyte\-colony stimulating factor(G\-CSF), etc. within one year before participating in a clinical trial
  • ¦ Accompanied by a serious disease, such as chromosome abnormality, etc.
  • ¦ In case where a patient’s medical condition is judged to be maladapted by a researcher
  • ¦ In case a patient or his/her legal representative doesn’t agree to participation in a clinical trial
  • ¦ A patient having a medical history of hypersensitivity to Granulocyte\-colony stimulating factor(G\-CSF)
  • ¦ A patient having a predisposition to allergies
  • ¦ A patient having serious disorders in the liver, kidney, and cardiopulmonary function

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Pilot study about the use of intravenous Vitamin C for the prevention of Reperfusion Syndrome in Orthotopic Liver Transplantation from a cadaver donor.
EUCTR2020-000123-39-ESFundación Investigación Biomédica Hospital Ramón y Cajal70
Not yet recruiting
Phase 2
Evaluation of G-CSF treatment of patients with chagasic cardiomyopathy.
RBR-6tnw2bFundação Oswaldo Cruz
Active, not recruiting
Phase 1
Double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responders patients experiencing a major depressive episodeDepressionMedDRA version: 20.0Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2018-002901-68-FRMAPREG110
Not yet recruiting
Phase 2
Phase II clinical trial, controlled, randomized, double-blind to assess the immunogenicity of live attenuated vaccine candidate against cholera CV638 .Cholera infection
RPCEC00000188Finlay Institute, Center for Research Developing and Productions of Vaccines410
Active, not recruiting
Phase 1
Clinical trial with L-asparaginase encapsulated in erythrcoytes in patients affected by metastatic pancreatic cancer after first line treatmentPancreatic cancerMedDRA version: 16.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-004262-34-FRERYTECH Pharma90